Compass Therapeutics, Inc. (CMPX)
0.611
0.00 (0.00%)
USD |
NASDAQ |
Nov 18, 16:00
0.63
+0.02
(+3.11%)
After-Hours: 07:43
Compass Therapeutics Enterprise Value : -43.79M for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | -43.79M |
| November 17, 2026 | -44.56M |
| November 16, 2026 | -34.70M |
| November 13, 2026 | -14.47M |
| November 12, 2026 | -6.152M |
| November 11, 2026 | -4.315M |
| November 10, 2026 | -2.910M |
| November 09, 2026 | -3.108M |
| November 06, 2026 | -17.17M |
| November 05, 2026 | -30.54M |
| November 04, 2026 | -16.47M |
| November 03, 2026 | -18.22M |
| November 02, 2026 | -15.61M |
| October 30, 2026 | -12.18M |
| October 29, 2026 | -17.64M |
| October 28, 2026 | -16.90M |
| October 27, 2026 | -19.23M |
| October 26, 2026 | -19.26M |
| October 23, 2026 | -16.78M |
| October 22, 2026 | -9.484M |
| October 21, 2026 | -7.142M |
| October 20, 2026 | -3.757M |
| October 19, 2026 | -3.450M |
| October 16, 2026 | 1.052M |
| October 15, 2026 | 7.661M |
| Date | Value |
|---|---|
| October 14, 2026 | 4.473M |
| October 13, 2026 | 0.5114M |
| October 12, 2026 | 15.01M |
| October 09, 2026 | 25.00M |
| October 08, 2026 | 23.27M |
| October 07, 2026 | 29.87M |
| October 06, 2026 | 25.92M |
| October 05, 2026 | 19.17M |
| October 02, 2026 | 0.4574M |
| October 01, 2026 | 8.453M |
| September 30, 2026 | 33.47M |
| September 29, 2026 | 27.85M |
| September 28, 2026 | 29.65M |
| September 25, 2026 | 33.25M |
| September 24, 2026 | 34.15M |
| September 23, 2026 | 40.46M |
| September 22, 2026 | 53.06M |
| September 21, 2026 | 157.51M |
| September 18, 2026 | 171.92M |
| September 17, 2026 | 162.92M |
| September 16, 2026 | 159.32M |
| September 15, 2026 | 162.92M |
| September 14, 2026 | 182.73M |
| September 11, 2026 | 189.93M |
| September 10, 2026 | 198.93M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Viking Therapeutics, Inc. | 2.632B |
| Capricor Therapeutics, Inc. | 361.51M |
| Ardelyx, Inc. | 754.22M |
| Biomea Fusion, Inc. | 12.25M |
| ARS Pharmaceuticals, Inc. | 353.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.17M |
| Total Expenses (Quarterly) | 27.17M |
| EPS Diluted (Quarterly) | -0.1455 |
| Earnings Yield | -75.86% |
| Normalized Earnings Yield | -75.84 |